177 related articles for article (PubMed ID: 15015656)
21. 1p19q co-deleted oligodendroglioma metastatic to bone.
Greene J; Cadoo K; Ti J; O'Donnell N; Allcutt D; Farrell M; Grogan L
Clin Neuropathol; 2013; 32(2):139-41. PubMed ID: 23073167
[No Abstract] [Full Text] [Related]
22. Molecular genetic evidence for subtypes of oligoastrocytomas.
Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
[TBL] [Abstract][Full Text] [Related]
23. Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review.
Li G; Zhang Z; Zhang J; Jin T; Liang H; Gong L; Cui G; Yang H; He S; Zhang Y; Gao G
Diagn Pathol; 2014 Jan; 9():17. PubMed ID: 24447608
[TBL] [Abstract][Full Text] [Related]
24. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas.
Zhu JJ; Santarius T; Wu X; Tsong J; Guha A; Wu JK; Hudson TJ; Black PM
Genes Chromosomes Cancer; 1998 Mar; 21(3):207-16. PubMed ID: 9523195
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
[TBL] [Abstract][Full Text] [Related]
26. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
[TBL] [Abstract][Full Text] [Related]
27. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
29. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
30. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
[TBL] [Abstract][Full Text] [Related]
32. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
[TBL] [Abstract][Full Text] [Related]
33. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Ruiter M; Mehrkens JH; Kreth S; Tonn JC; Kretzschmar HA; Kreth FW
J Neuropathol Exp Neurol; 2009 Nov; 68(11):1219-28. PubMed ID: 19816195
[TBL] [Abstract][Full Text] [Related]
34. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M; Fortin D; Tsanaclis AM; Drouin R
Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
[TBL] [Abstract][Full Text] [Related]
35. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
36. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia.
He J; Hoang-Xuan K; Marie Y; Leuraud P; Mokhtari K; Kujas M; Delattre JY; Sanson M
Neurology; 2000 Sep; 55(6):867-9. PubMed ID: 10994011
[TBL] [Abstract][Full Text] [Related]
37. Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q.
Vajtai I; Arnold M; Vassella E
Acta Neuropathol; 2005 Nov; 110(5):520-2. PubMed ID: 16222523
[No Abstract] [Full Text] [Related]
38. Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity--case report.
Noshita N; Mashiyama S; Fukawa O; Asano S; Watanabe M; Tominaga T
Neurol Med Chir (Tokyo); 2010; 50(2):161-4. PubMed ID: 20185886
[TBL] [Abstract][Full Text] [Related]
39. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
40. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D
J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
